US 11364235
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
granted A61KA61K2039/545A61K31/496
Quick answer
US patent 11364235 (Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic) held by Actinium Phamaceuticals, Inc. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Actinium Phamaceuticals, Inc.
- Grant date
- Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/545, A61K31/496, A61K31/635, A61K39/3955